Stockscreener 앱 받기
123.76
1.35%
-1.69
시간 외 거래:
122.48
-1.28
-1.03%
전일 마감가:
$125.45
열려 있는:
$125.845
하루 거래량:
14.08M
Relative Volume:
2.10
시가총액:
$153.66B
수익:
$29.79B
순이익/손실:
$9.22B
주가수익비율:
16.84
EPS:
7.3494
순현금흐름:
$10.23B
1주 성능:
-1.68%
1개월 성능:
-4.56%
6개월 성능:
+1.89%
1년 성능:
+14.59%
1일 변동 폭
$122.43
$126.39
1주일 범위
$122.43
$128.20
52주 변동 폭
$104.46
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
123.76 | 153.66B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,098.57 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.39 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
216.49 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
113.87 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
147.08 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences (GILD) Gets a Buy from Scotiabank - The Globe and Mail
Gilead Sciences stock price forecast: $120.19 support in focus as GILD slides 1.82% - Traders Union
Gilead’s Work to Help End the HIV Epidemic, One Year after Launch of its Twice-Yearly Prevention Medication - Gilead Sciences
Vascular Dementia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare - Barchart.com
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Gilead Sciences Cell Therapy Move Draws Biotech Attention - Kalkine Media
Gilead Sciences StockFDA accepts filing for weekly HIV prevention pill - AD HOC NEWS
World Economic Forum, Takeda and Gilead executives confirmed for Women's HealthX in Boston - FemTech World
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Why Gilead Sciences bets on Sunlenca as a long-acting HIV anchor - AD HOC NEWS
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Pharma Giants Navigate A Busy Deal-Making Backdrop - Kalkine Media
Gilead Sciences (GILD) Donates Remdesivir to Uganda - Yahoo Finance
Gilead Sciences Inc (GILD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Voya Global High Dividend Low Volatility Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD) - The Globe and Mail
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK - The Globe and Mail
Gilead Sciences chief comm officer sells $371k in stock - Investing.com India
[Press release] FDA accepts Gilead’s application for investigational once-weekly oral Yeztugo, potentially the first long-acting pill for HIV prevention - European AIDS Treatment Group
Gilead Sciences chief comm officer sells $371k in stock By Investing.com - Investing.com Nigeria
Gilead (NASDAQ: GILD) officer sells 3,000 shares under 10b5-1 plan - Stock Titan
Gilead Sciences Insider Sold Shares Worth $376,200, According to a Recent SEC Filing - marketscreener.com
Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 trade - Stock Titan
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention - Yahoo Finance UK
Gilead Sciences Stock (US3755581036): Quarterly earnings trends keep the biotech in focus - AD HOC NEWS
Once-weekly HIV prevention push, Gilead’s Yeztugo tablet moves toward FDA review - AD HOC NEWS
Gilead Sciences (GILD) Seeks FDA Approval for Weekly HIV Prevention Pill - GuruFocus
GILD Receives FDA Acceptance for Yeztugo as HIV Preventative - GuruFocus
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
FDA accepts Gilead application for once-weekly oral HIV prevention pill - Investing.com Canada
Director sale notice: GILD (NASDAQ: GILD) files Form 144 for 9,000 shares - Stock Titan
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention - Business Wire
Morgan Stanley files Rule 144 for GILD common shares (GILD) - Stock Titan
Regulatory Milestone Boosts Gilead’s Presence in Liver Disease Care - Insider Monkey
Former Gilead COO Asks Judge to Nix `Rape’ in Woman’s Harassment Trial - MyNewsLA.com
Gilead Sciences Patent Application Challenged Over Potential Impact on ARIPO Contracting States - pan african visions
Panagora Asset Management Inc. Sells 321,348 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Public Employees Retirement Association of Colorado Has $111.55 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Resources Management Corp CT ADV Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Arax Advisory Partners Has $3.60 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Atlas Capital Advisors Inc. Takes $1.01 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc.: - marketscreener.com
Gilead Sciences, Inc. $GILD Shares Acquired by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
177,100 Shares in Gilead Sciences, Inc. $GILD Purchased by Adams Diversified Equity Fund Inc. - MarketBeat
Gilead Sciences (GILD) Reports Positive Phase 3 IDEAL Results for Livdelzi in PBC - Insider Monkey
Victory Capital Management Inc. Sells 109,808 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by State Street Corp - MarketBeat
Gilead (GILD) Supports Faster South Africa Access to Lenacapavir - Insider Monkey
Martingale Asset Management L P Acquires 21,153 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.74%
자본화:
|
볼륨(24시간):